MedEffect Canada

As part of its regulatory responsibility, Health Canada conducts consultations in the area of post-market surveillance, primarily adverse reaction reporting, of drugs and health products. Participants' comments and ideas contribute to the development of strategic priorities for these programs, helping us define what they should strive to achieve in the short, medium and long-term.

Current Consultations

• Draft Revised Guidance Document - Review of Drug Names for Look-alike Sound-alike (LASA) Attributes [2013-02-19]

Past Consultations

2011

• Draft Guidance Document - Product Monograph - Part III: Consumer Information [2011-07-21]

2010

• Consultation - Draft Health Product Vigilance Framework

2009

• Consultation on the Regulatory Amendment to the Adverse Drug Reaction Reporting Section of the Food and Drug Regulations - Canada Gazette Part I